v3.25.3
Liabilities Related to Business Combinations and to Non-Controlling Interests (Tables)
 6 Months Ended
Jun. 30, 2025
Disclosure of contingent liabilities in business combination [abstract]  
Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests
Movements in liabilities related to business combinations and to
non-controlling
interests in the first half of 2025 are shown below:
 
 (
€
 million)
   
MSD contingent
consideration
(European
Vaccines
business)
    
Shire contingent
consideration
arising from
acquisition of
Translate Bio
    
Other
     
Total
 (a)
  
Balance at January 1, 2025
   
 
72
 
  
 
568
 
  
 
1
 
   
 
641
 
         
Payments made
   
 
(72
) 
  
 
—
 
  
 
—
 
   
 
(72
) 
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)
(b)
   
 
1
 
  
 
71
 
  
 
—
 
   
 
72
 
Currency translation differences
   
 
(1
) 
  
 
(76
) 
  
 
—
 
   
 
(77
) 
Balance at June 30, 2025
   
 
—
 
  
 
563
 
  
 
1
 
   
 
564
 
Of which:
          
• Current portion
          
 
—
 
•
Non-current
portion
   
 
 
 
  
 
 
 
  
 
 
 
   
 
564
 
 
(a)
As of January 1, 2025, this comprised a
non-current
portion of €569 million and a current portion of €72 million.
(b
Amounts mainly reported within the income statement line item “Fair value remeasurement of contingent consideration”.